A5091664176- Diabetes Treatment and Management
- Health Systems, Economic Evaluations, Quality of Life
- Heart Failure Treatment and Management
- Diabetes Management and Research
- Medication Adherence and Compliance
- Asthma and respiratory diseases
- Chronic Kidney Disease and Diabetes
- Antiplatelet Therapy and Cardiovascular Diseases
- Lipoproteins and Cardiovascular Health
- Cardiovascular Function and Risk Factors
- Pharmaceutical Economics and Policy
- Atrial Fibrillation Management and Outcomes
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Cardiac pacing and defibrillation studies
- Metabolism, Diabetes, and Cancer
- Blood Pressure and Hypertension Studies
- Potassium and Related Disorders
- Health Promotion and Cardiovascular Prevention
- Venous Thromboembolism Diagnosis and Management
- Respiratory and Cough-Related Research
- Healthcare cost, quality, practices
- Inflammatory mediators and NSAID effects
- Healthcare Policy and Management
- Nutritional Studies and Diet
- Pharmaceutical studies and practices
AstraZeneca (Spain)
2016-2025
University of Cambridge
2024
AstraZeneca (Brazil)
2020
Bellvitge University Hospital
2020
Hospital Universitario Lucus Augusti
2020
Hospital Universitario La Paz
2020
Oblikue Consulting (Spain)
2015
Hospital Universitari de Girona Doctor Josep Trueta
2015
AstraZeneca (United Kingdom)
2010-2014
Health Economics and Outcomes Research (United Kingdom)
2012
Abstract Background Increasing the knowledge about heart failure (HF) costs and their determinants is important to ascertain how HF management can be optimized, leading a significant decrease of costs. This study evaluated cumulative healthcare utilisation in patients Spain. Methods Observational, retrospective, population-based using BIG-PAC database, which included data from specialized primary care people ≥18 years, seven autonomous communities Spain, who received for between 2015 2019....
Objective. To analyze the clinical characteristics of patients taking Factor Xa inhibitors (FXai), either direct FXai or enoxaparin (only in active cancer patients), and to estimate incidence risk factors for major bleeding during use. Methods. A retrospective cohort study, which included secondary data from computerized health records primary care centers hospitals seven Spanish Autonomous Communities. Results. 9374 were analyzed, with 8972 402 enoxaparin. At baseline, mean age (SD) was...
Objective: To analyze clinical characteristics of non-anticoagulated subjects with major bleeding, and to determine the incidence adverse events, healthcare resource utilization (HCRU) associated costs following a bleeding event. Methods: Retrospective observational cohort study that analyzed secondary data from electronic health records in Spain. Non-anticoagulated patients first during period (between January 2013 December 2022) were for 3 years. Results: A total 4089 (mean age 57.26...
To describe the epidemiology, clinical profile, treatments, and to determine cardiovascular renal outcomes after two years of follow-up in a contemporary chronic kidneay disease (CKD) population Spain. This was also analyzed among DAPA-CKD-like (patients who met most inclusion criteria DAPA-CKD trial). Observational, retrospective, population-based study using BIG-PAC database. The CKD defined as patients ≥18 years, with at least one diagnostic code prior index date (January 1st, 2018)....
Objective: We determined the percentage of patients with severe asthma and exacerbations evaluated costs disease based on blood eosinophil counts.Methods: A retrospective observational study review medical records in Spain was carried out. Patients ≥18 years age requiring care during 2014-2015; diagnosed at least 2 continuous (at one year prior to index date defined as first medication prescription after date) were included. Study groups: counts <300 cells/μl ≥300 cells/μl. Main variables:...
Data about the impact of chronic kidney disease (CKD) on health care costs in Spain are scarce This study was aimed to evaluate cumulative and healthcare utilisation CKD Spain.
Objective. To study the effectiveness and safety in a real-life setting of budesonide/formoterol (Symbicort) Maintenance And Reliever Therapy® (Symbicort SMART®), simplified management approach with one inhaler, compared conventional best practice (CBP) multiple inhalers patients persistent asthma. Design. Open-label randomized controlled parallel-group trial, 6-month treatment. Participants. A total 654 adult patients, asthma receiving treatment inhaled corticosteroids (ICS), either alone...
To describe the epidemiology, clinical profile, treatments, and to determine cardiovascular renal outcomes after two years of follow-up in a contemporary chronic kidneay disease (CKD) population Spain. This was also analyzed among DAPA-CKD-like (patients who met most inclusion criteria DAPA-CKD trial).
To analyse and compare the impact of cardiovascular risk factors disease on health-related quality life (HRQoL) in people with without diabetes living community.We used data 1,905 19,031 from last Spanish National Health Survey (years 2011-2012). The HRQoL instrument was EuroQol 5D-5L, based time trade-off scores. Matching methods were to assess any differences same characteristics (age, gender, education level, healthy lifestyle), according diseases. Disparities also analysed for every...
The objective of this study was to carry out a long-term cost-effectiveness analysis rosuvastatin compared with generic atorvastatin in the treatment patients at high cardiovascular (CV) risk (≥ 5% Systematic COronary Risk Evaluation [SCORE]) and prior disease (CVD) Spain.The efficacy data from Statin Therapies for Elevated Lipid Levels Across doses Rosuvastatin (STELLAR) were used simulate achievement low-density lipoprotein cholesterol targets different an initial period 1 year. A Markov...
Aims: Our aims were to describe the clinical characteristics, adverse events, healthcare resource utilization (HCRU) and costs of patients with major bleeding during direct Factor Xa inhibitor (FXai) use. Methods: This is a retrospective cohort study that included secondary data from computerized health records seven Spanish Autonomous Communities. Patients first treatment FXai analyzed 3-year period. Results: Of 8972 taking FXai, 470 (5.24%) had (mean age (SD) 77.93 (9.71) years, 61.06%...
There is scarce information on patients with secondary heart failure diagnosis (sHF). We aimed to compare the characteristics, burden, and outcomes of sHF those primary HF (pHF). Retrospective, observational study ≥18 years emergency department (ED) visits during 2018 pHF in ED or hospital (ICD-10-CM) diagnostic codes. Baseline 30-day 1-year mortality, readmission re-ED visit rates, costs were compared between pHF. Out 797 discharged home from ED, 45.5% had sHF, these presented lower...
The objective of this study was to carry out a cost-effectiveness analysis dapagliflozin, as an add-on therapy standard care (SoC), for the treatment type 2 diabetes mellitus (T2DM) in Spain, based on results DECLARE-TIMI 58 trial.
The aim of this study was to assess the efficiency exenatide 2 mg/week compared with other glucagon-like peptide-1 (GLP-1) receptor agonists (dulaglutide 1.5 mg/week, liraglutide 1.2 mg/day, 1.8 mg/day and lixisenatide 20 μg/day) in adult patients type diabetes mellitus (T2DM) not adequately controlled on metformin alone from perspective Spanish National Health System (NHS).
Objective: To determine the relationship between short-acting ß-adrenergic agonist (SABA) overuse and health care resource use costs in asthma patients routine clinical practice. Methods: A longitudinal retrospective study was conducted Spanish primary specialized centers using BIG-PAC medical records database. The population comprised ≥12 years of age who attended ≥2 consultations during 2017 had 1-year follow-up data available. main outcomes were demographics, comorbidities, medication,...
Antecedentes y objetivos: La enfermedad renal crónica (ERC) es un problema de salud creciente que afecta entre el 10% 15% la población española. escasez proyecciones actualizadas sobre evolución carga obstaculiza desarrollo políticas e intervenciones sanitarias basadas en evidencia para optimizar manejo prevenir su progresión. El objetivo este estudio proyectar clínica económica ERC España 2022 2027. Materiales métodos: Inside CKD utiliza enfoque microsimulación validado analizar proyectada...
Antecedentes y objetivos: La enfermedad renal crónica (ERC) es un grave problema de salud cuyo impacto clínico, social económico se incrementa en estadios avanzados. Dapagliflozina inhibidor del cotransportador sodio-glucosa-2 que reduce el riesgo progresión la ERC, además proporcionar beneficios cardiovasculares reducir mortalidad por cualquier causa. El objetivo este trabajo determinar clínico a corto plazo adición dapagliflozina terapia estándar con inhibidores sistema renina angiotensina...